Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
Eli Lilly••business
Key Points:
- Eli Lilly has entered a definitive agreement to acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company developing oral small molecule therapies targeting chronic inflammation, for approximately $1.2 billion in an all-cash transaction.
- Ventyx's pipeline includes NLRP3 inhibitors and other compounds aimed at treating a broad range of inflammation-mediated diseases such as cardiometabolic disorders, neurodegenerative diseases, inflammatory bowel disease, and autoimmune conditions.
- The acquisition strengthens Lilly's capabilities in inflammatory-mediated diseases and supports its focus on developing innovative oral drugs with improved efficacy and safety profiles for chronic diseases driven by inflammation.
- The transaction, approved by both companies' boards, is expected to close in the first half of 2026, subject
:max_bytes(150000):strip_icc()/GettyImages-22400154171-19eb2573d96647f8894478942b5721be.jpg)
